BioCryst Pharmaceuticals, Inc. (BCRX) Balance Sheet

The balance sheet remains deeply negative, with equity improving only marginally from -$475.9M to -$454.3M over the period, despite strong top-line growth. This suggests that while operations are scaling, the company is still consuming capital faster than it generates retained earnings, likely due to one-time charges and acquisition-related outflows. The trajectory indicates a slow but positive trend toward balance sheet repair, but the pace is insufficient to offset accumulated deficits.

Debt levels have been volatile, dropping sharply in 2026Q2, but the negative equity base means leverage metrics are not meaningful. The company's cash-to-debt ratio is low, with cash at $155.0M against $409.9M debt, suggesting limited near-term liquidity buffer. This may indicate reliance on refinancing or additional financing, which could be challenging given the negative equity position.

The asset base is dominated by cash and receivables, with negligible fixed assets, consistent with outsourced manufacturing. The absence of goodwill suggests no significant acquisitions have been capitalized, but the $489.5M acquisition outflow in Q1 2026 may indicate an asset purchase not yet reflected in goodwill. Investors should monitor whether future impairments could arise from any acquired intangibles.

The equity deficit has widened, driven by cumulative losses and stock-based compensation, which totaled over $200M in the period. While the company is now generating positive operating income, the balance sheet remains structurally weak, with negative equity of -$454.3M. This suggests that the company is not yet self-funding on a GAAP basis, and the equity position may limit financial flexibility.

The current ratio remains above 2, suggesting adequate short-term liquidity, but the cash balance is modest relative to debt obligations. The company's ability to service debt without dilutive financing is uncertain, especially given the negative equity. The positive free cash flow in recent quarters provides some cushion, but the low cash-to-debt ratio warrants close monitoring.